Pfizer's static Q3 sales buoyed by international growth

Share this article:
Pfizer reported static third quarter revenues of $12 billion, with solid international sales offsetting weaker US sales for several key products.

Pharmaceutical revenues were down 1% for the quarter year-on-year to $11 billion, with the favorable impact of foreign exchange helping offset the loss of US exclusivity on Norvasc, Zyrtec and Camptosar.

Lipitor revenues were down 1% to $3.1 billion for the quarter as a 16% increase in international sales compensated for a 13% drop in US sales. Lyrica revenues shot up 45% to $675 million, with international revenues up 51% and US revenues up 40%. Celebrex revenues were up 8%, with international revenues increasing 21% and US revenues up 4%. Sutent revenues were up 49% on strong international growth – international sales rose 79%, while US sales rose a mere 4%. And Chantix revenues were down 24% due to a 49% decline in US sales, while international sales rose 60%.

Pfizer recently scrapped its regional business units in favor of global organizations, creating new units to house development and commercial operations for primary care, specialty therapeutics and emerging markets such as Russia, China, India and Turkey. At the same time the company signaled plans to focus more on international markets amid slowing US sales growth.  
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.